1Jagannathan J, Prevedello DM, Dumont AS, et al. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme [ J ]. Neurosurg Focus, 2006, 20(4) : E8.
2Brandes AA, Franceschi E, Tosoni A, et al. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments [ J]. Clin Cancer Res, 2008, 14(4) : 957 -960.
3Cao Z, Liu LZ, Dixon DA, et al. Insulin-like growth factor-Ⅰ induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells [ J]. Cell Signal, 2007, 19 (7) : 1542-1553.
4Ran H, Yang BF, Rainov NG. Receptor tyrosine kinases as therapeutic targets in malignant glioma [ J]. Rev Recent Clin Trials, 2007, 2 ( 2 ) : 87 - 101.
5Kaul A, Overmeyer JH, Maltese WA. Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathways [J]. Cell Signal, 2007, 19(5) : 1034 - 1043.
6Kieran MW. Anti-angiogenic chemotherapy in central nervous system tumors [J]. Cancer Treat Res, 2004, 117:337-349.
7Vredenburgh JJ, Desjardins A, Hemdon JE 2nd, et al. Phase Ⅱ trial of bevaeizumab and irinotecan in reeurrent malignant glioma [ J ]. Clin Cancer Res, 2007, 13(4) : 1253 - 1259.
8Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap ( VEGF Trap) to inhibit vascular endothelial growth factor activity [ J ]. Clin Colorectal Cancer, 2004, 4 ( Suppl 2) : S81 - 85.
9Reardon DA, Egorin M J, Quinn JA, et al. Phase Ⅱ study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma muhiforme [J]. J Clin Oncol, 2005, 23(36) : 9359 -9368.
10Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase Ⅱ study of imatinib mesylate and hydroxyurea for recurrent grade Ⅲ malignant gliomas [ J]. J Neurooncol, 2007, 83 (1): 53- 60.
5Shai RM, Reichardt JK, Chen TC. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas[ J]. Future Oncol, 2008,4(4) :525 - 534.
6Sanson M. Editorial review: targets for glioma treatment: from bench to bedside [ J ]. Curr Opin Oncol, 2008, 20 (6) : 650 - 651.
7Sorensen AG, Batchelor TT, Wen PY, et al. Response criteria for glioma[J]. Nat Clin Pract Oncol, 2008, 5(11) :634-644.
8Brandsma D, de Bruin HG, Bromberg JE, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide [ J ]. Cancer, 2008, 113(2) :405 -410.
9Salmaggi A, Silvani A, Merli R, et al. Muhicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience [J]. Neurol Sci, 2008, 29(2) : 77 -83.
10Diete S, Treuheit T, Dietzmann K, et al. Sex differences in length of survival with malignant astrocytoma, but not with glioblastoma [ J ]. J Neurooncol, 2001, 53 (1): 47-49.
